top of page

GLP-1 Medications and Nutrition: What Every Patient Needs to Know

  • Writer: Nicole Barrato
    Nicole Barrato
  • Jul 15, 2023
  • 2 min read

Updated: 4 hours ago

GLP-1 receptor agonists — medications including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — have transformed the clinical management of type 2 diabetes and obesity. A pivotal trial published in the New England Journal of Medicine in 2021 found that once-weekly semaglutide produced an average weight loss of nearly 15 percent of body weight over 68 weeks — results previously achievable only through bariatric surgery. These medications work by mimicking the GLP-1 hormone, which delays gastric emptying, reduces appetite and improves insulin secretion. As their prescription volume has surged, we are fielding more questions about them than ever before.

The critical clinical message is this: GLP-1 medications are not a substitute for nutrition counseling — they make it more necessary. These medications dramatically reduce appetite and food intake, which creates a genuine risk of nutritional inadequacy. Patients taking GLP-1 agents commonly experience reduced tolerance for larger food volumes, food aversions and changes in taste preferences. Without intentional focus on nutrient density, protein adequacy and micronutrient intake, patients can lose significant muscle mass alongside fat — an outcome that undermines the long-term benefits of the medication.

At NutriGreene, we offer dedicated GLP-1 nutrition support services precisely because we recognized early that patients starting these medications needed specialized dietitian guidance. Working with a registered dietitian while on a GLP-1 medication helps you maximize its benefits, minimize muscle loss, address common side effects through dietary modification and build the long-term habits that will matter when medication is eventually discontinued.

Sources

  • Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.

  • Davies M, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984.

Ready to take the next step in your nutrition journey? Schedule an appointment at NutriGreene today. www.nutrigreene.com | (203) 429-4211 | info@nutrigreene.com

Comments


bottom of page